CANNAINVESTOR Magazine August 2016 - Page 44

Cara Therapeutics Reports 2Q16 Financial Results

GlobeNewswire•August 4, 2016

– Resumed patient enrollment in adaptive pivotal trial of I.V. CR845 in post-operative pain

– Initiated adaptive Phase 2/3 trial for I.V. CR845 in dialysis patients with uremic pruritus

– Initiation of Phase 2b trial of Oral CR845 in osteoarthritis patients expected in Q3, 2016

STAMFORD, Conn., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (CARA), a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial results for the second quarter ended June 30, 2016.

“This quarter we were pleased to resume enrollment in the adaptive pivotal trial of I.V. CR845 for postoperative pain, as well as initiate our adaptive Phase 2/3 trial in dialysis patients suffering from moderate-to-severe uremic pruritus,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “With both studies enrolling on schedule and our Phase 2b trial of Oral CR845 in osteoarthritis expected to begin in the third quarter of this year, Cara will soon have three ongoing late-stage studies addressing distinct clinical populations.”

Second Quarter and Recent Business Highlights

In June 2016, resumed patient enrollment for the adaptive Phase 3 trial of I.V. CR845 in postoperative pain. The trial continues as a three-arm trial testing two doses of CR845 (1.0 ug/kg and 0.5 ug/kg) versus placebo.

In June 2016, initiated an adaptive Phase 2/3 trial of I.V. CR845 for the treatment of chronic kidney disease-associated, or uremic pruritus, for which there are no approved therapies in the United States.

Presented positive data from the Phase 2a study of the oral formulation of CR845 in osteoarthritis patients, as well as data from the human abuse liability study of I.V. CR845 showing low potential for human abuse at the 2016 International Conference on Opioids.

To view entire press release please visit

2Q16 Highlights